AVENUE THERAPEUTICS INC (ATXI)       10.08  +2.83 (+39.03%)

Company Profile

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2017-06-27. The firm seeks to develop and commercialize its product principally for use in the acute/intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, for the treatment of post-operative acute pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. The company also works through the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. These opioid and non-opioid modes of action are synergistic, providing multimodal therapy with the use of a single drug. Tramadol is marketed as an oral agent indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Ultracet, a combination product containing tramadol and acetaminophen, is also marketed in the United States (Ortho-McNeil-Janssen).

Company Info

AVENUE THERAPEUTICS INC

2 Gansevoort St Fl 9

New York City NEW YORK 10036

P: 17816524500.0

CEO: Lucy Lu

Employees: 4

Website: http://www.avenuetx.com/